Skip to main content

Table 2 Clinical features in patients with Sweet's syndrome

From: Sweet's syndrome – a comprehensive review of an acute febrile neutrophilic dermatosis

 

Clinical Form

Characteristic

Classicala

Hematologic malignancya

Solid tumora

Drug-inducedb

Epidemiology

    

Women

80

50

59

71

Prior upper respiratory tract infection

75–90

16

20

21

Recurrencec

30

69

41

67

Clinical symptoms

    

Feverd

80–90

88

79

100

Musculoskeletal involvement

12–56

26

34

21

Ocular involvement

17–72

7

15

21

Lesion location

    

Upper extremities

80

89

97

71

Head and neck

50

63

52

43

Trunk and back

30

42

33

50

Lower extremities

Infrequent

49

48

36

Oral mucous membranes

2

12

3

7

Laboratory findings

    

Neutrophiliae

80

47

60

38

Elevated erythrocyte sedimentation ratef

90

100

95

100

Anemiag

Infrequent

82

83

100

Abnormal platelet counth

Infrequent

68

50

50

Abnormal renal functioni

11–50

15

7

0

  1. aPercentages for classical, hematologic malignancy, and solid tumor associated Sweet's syndrome adapted with permission from Cohen PR, Kurzrock R: Sweet's syndrome and cancer. Clin Dermatol 1993;11:149–157 [15]. Copyright 1993, Reprinted with permission from Elsevier Ltd, Oxford, United Kingdom.
  2. bPercentages for drug-induced Sweet's syndrome adapted with permission from Walker DC, Cohen PR: Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug induced Sweet's syndrome. J Am Acad Dermatol 1996;34:918–923 [13]. Copyright 1996, Reprinted with permission from the American Academy of Dermatology, Inc., Elsevier Ltd, Oxford, United Kingdom.
  3. cRecurrence following oral rechallenge testing in the patients with drug-induced Sweet's syndrome.
  4. dTemperature greater than 38°C.
  5. eNeutrophil count greater than 6,000 cells/ul.
  6. fErythrocyte sedimentation rate greater than 20 mm/hr.
  7. gHemoglobin less than 13 g/dl in men and less than 12 g/dl in women.
  8. hPlatelet count less than 150,000/ul or greater than 500,000/ul.
  9. iThis includes hematuria, proteinuria, and renal insufficiency.